Home Watchlists Portfolios Indices Forex Futures Comparisons Alerts Screeners Scans Charts Settings

Arvinas (NASDAQ:ARVN) Upgraded at Zacks Investment Research

  • Source: Slater Sentinel - - Read: 0



    Zacks Investment Research upgraded shares of Arvinas (NASDAQ:ARVN) from a sell rating to a hold rating in a research note issued to investors on Monday morning, Zacks.com reports.

    According to Zacks, “Arvinas Inc. is a biopharmaceutical company for patients suffering from debilitating and life-threatening diseases. It engages in the discovery, development and commercialization of therapies to degrade disease-causing proteins. Arvinas Inc. is based in CT, United States. “

    Several other research firms have also weighed in on ARVN. Wedbush initiated coverage on Arvinas in a report on Tuesday, September 24th. They set an outperform rating and a $38.00 target price on the stock. Cantor Fitzgerald initiated coverage on Arvinas in a report on Monday, August 5th. They set an overweight rating ...



    Read Full News: https://slatersentinel.com/news/2019/10/12/arvinas-nasdaqarvn-upgraded-at-zacks-investment-research.html

Log in to reply